A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus

详细信息    查看全文

• 作者：Gerlinde R. Van de Walle ; Maeva A. May ; Sarah T. Peters ; Stephan M. Metzger ; Cristina T. Rosas ; Nikolaus Osterrieder
• 关键词：MLV ; EHV-1 ; Abortigenic ; EIV
• 刊名：Vaccine
• 出版年：2010
• 出版时间：22 January 2010
• 年：2010
• 卷：28
• 期：4
• 页码：1048-1055
• 全文大小：568 K

文摘

Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03. The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03. Induction of a robust EHV-1-specific immune response was observed. Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels. In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro. Vaccination of horses resulted in the induction of a robust serological immune responses against two recent but genetically distinct EIV representatives, VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease.